Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6872107 | 0.89 | PDE2A (0.38) | PDE2AGRIN2BSCN9ATP53MAPT | |
| SCHEMBL6870210 | 0.87 | GRM2 (0.38) | PDE2AMAPT | |
| SCHEMBL6869734 | 0.85 | CASR (0.35) | PDE2ASCN9ATP53MAPTMKNK2 | |
| SCHEMBL6871205 | 0.85 | ICMT (0.35) | PDE2AGRIN2BMAPTKDM4E | |
| SCHEMBL6872057 | 0.82 | GRIN2B (0.42) | GRIN2BTP53MAPT | |
| SCHEMBL6871072 | 0.80 | GRIN2B (0.38) | GRIN2BTP53MAPTKDM4ECTSS | |
| SCHEMBL6872010 | 0.80 | SCN9A (0.35) | PDE2ASCN9ATP53MAPTMKNK2 | |
| SCHEMBL6871183 | 0.78 | GRIN2B (0.45) | GRIN2BTP53 | |
| SCHEMBL27816857 | 0.77 | PDE2A (0.33) | PDE2AGRIN2BSCN9AKDM4ETDP1 | |
| SCHEMBL2045423 | 0.76 | TDP1 (0.34) | PDE2ASCN9AMAPTKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367812-B1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4TRIFLUOROMETHOXY-1H-INDOL-3-YL]METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| EP-2367812-B1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4TRIFLUOROMETHOXY-1H-INDOL-3-YL]METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| CN-102149705-B | [4- (5-aminomethyl-2-fluorophenyl) -piperidin-1-yl ] - [ 7-fluoro-1- (2-methoxyethyl) -4-trifluoromethoxy-1H-indol-3-yl ] -methanone as mast cell tryptase inhibitor | SANOFI AVENTIS | 2013-08-07 | — | — | CN | disclosed |
| US-8497379-B2 | Method and intermediates for the preparation of 2,2,2-trifluoro-N-(4-fluoro-3-pyridin-4-yl-benzyl)-acetamide hydrochloride | SANOFI (FR) | 2013-07-30 | — | — | US | disclosed |
| US-8497379-B2 | Method and intermediates for the preparation of 2,2,2-trifluoro-N-(4-fluoro-3-pyridin-4-yl-benzyl)-acetamide hydrochloride | SANOFI (FR) | 2013-07-30 | — | — | US | disclosed |
| US-8497379-B2 | Method and intermediates for the preparation of 2,2,2-trifluoro-N-(4-fluoro-3-pyridin-4-yl-benzyl)-acetamide hydrochloride | SANOFI (FR) | 2013-07-30 | — | — | US | disclosed |
| EP-2538942-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2013-01-02 | — | — | EP | disclosed |
| CN-102858336-A | Treatment of skin allergic symptoms | SANOFI SA | 2013-01-02 | — | — | CN | disclosed |
| US-20120309790-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2012-12-06 | — | — | US | disclosed |
| US-20120309790-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2012-12-06 | — | — | US | disclosed |
| WO-2011106334-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2011-09-01 | — | — | WO | disclosed |
| US-20110201647-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201647-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201647-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| CN-102149705-A | [4- (5-aminomethyl-2-fluorophenyl) -piperidin-1-yl ] - [ 7-fluoro-1- (2-methoxyethyl) -4-trifluoromethoxy-1H-indol-3-yl ] -methanone as mast cell tryptase inhibitor | SANOFI AVENTIS | 2011-08-10 | — | — | CN | disclosed |
| WO-2011079103-A1 | SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011078983-A1 | TREATMENT FOR INFLAMMATORY BOWEL DISEASE | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011078983-A1 | TREATMENT FOR INFLAMMATORY BOWEL DISEASE | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010022196-A2 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022196-A2 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201647-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | CMA1, TPSAB1, TPSB2 | PDE2A 1231/4885GRIN2B 3649/4885SCN9A 2186/4885 |
| US-20120309790-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | TSLP, CMA1, TPSG1 | PDE2A 3158/4885GRIN2B 2163/4885SCN9A 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.